Skip to main content Skip to main navigation menu Skip to site footer

Admission C-reactive protein, D-dimer, IL-6 and XCL1/lymphotactin levels as predictors of 28-day mortality in COVID-19 patients: a prospective cohort study

  • Adityo Susilo ,
  • Herdiman Theodorus Pohan ,
  • Cleopas Martin Rumende ,
  • Iris Rengganis ,
  • Alida Harahap ,
  • Aria Kekalih ,
  • Dewi Wulandari ,
  • Ivo Novita Sahbandar ,
  • Suhendro Suwarto ,


Link of Video Abstract:


Background: Predictors of mortality in COVID-19 patients, which are essential factors in guiding patient management, are poorly understood. In Indonesia, several inflammatory markers have been utilized to evaluate the severity of COVID-19. This study aimed to determine the role of C-reactive protein (CRP), D-dimer, interleukin-6 (IL-6), and XCL1/lymphotactin levels in predicting 28-day mortality in patients with COVID-19.

Methods: A prospective cohort study was conducted with COVID-19 patients admitted to the emergency department at Cipto Mangunkusumo Hospital and Medistra Hospital, Jakarta, Indonesia, from June 2020 to February 2021. The predictors of 28-day mortality in COVID-19 patients in this study included CRP, D-dimer, IL-6, and XCL1 levels at admission. Cox proportional hazard regression analysis was used to determine the independent predictors of 28-day mortality in the study population.

Results: A total of 120 patients with COVID-19 were enrolled in the study; 21 (17.5%) died within 28 days after admission. According to our multivariate analysis, a CRP level (HR, 8.55; 95% CI, 3.310-22.088) ≥ 110 mg/L and a D-dimer level (HR, 20.642; 95% CI, 6.909-61.667) ≥ 4640 ng/mL were identified as independent predictors of 28-day mortality in COVID-19 patients.

Conclusion: A C-reactive protein level ≥ 110 mg/L and a D-dimer level ≥ 4640 ng/mL can be used to predict 28-day mortality in COVID-19 patients.


  1. Zu ZY, Jiang M Di, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020;296(2):E15–25. Available from:
  2. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci. 2020;24(7):4016–26. Available from:
  3. World Health Organization. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. World Health Organization. 2021. Available from:
  4. Satuan Tugas Penanganan COVID-19. Peta Sebaran | [Internet]. 2021. Available from:
  5. Hartantri Y, Debora J, Widyatmoko L, Giwangkancana G, Suryadinata H, Susandi E, et al. Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia. The Lancet Regional Health - Southeast Asia. 2023;11.
  6. Lescure F, Bouadma L, Nguyen D, Parisey M, Wicky P, Behillil S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020;20(6):697–706. Available from:
  7. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. New England Journal of Medicine. 2020;382(12):1177–9. Available from:
  8. Rosas-Taraco AG, Higgins DM, Sánchez-Campillo J, Lee EJ, Orme IM, González-Juarrero M. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am J Respir Cell Mol Biol. 2009;41(2):136–45.
  9. Eljilany I, Elzouki AN. D-dimer, fibrinogen, and il-6 in covid-19 patients with suspected venous thromboembolism: A narrative review. Vasc Health Risk Manag. 2020;16:455–62.
  10. Pacheco JM, Smoliga GR, O’Donnell V, Brito BP, Stenfeldt C, Rodriguez LL, et al. Persistent Foot-and-Mouth Disease Virus Infection in the Nasopharynx of Cattle; Tissue-Specific Distribution and Local Cytokine Expression. PLoS One. 2015;10(5):e0125698.
  11. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–4.
  12. Zhang L, Long Y, Xiao H, Yang J, Toulon P, Zhang Z. Use of D‐dimer in oral anticoagulation therapy. Int J Lab Hematol. 2018;40(5):503–7.
  13. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020;18(4):844–7.
  14. Lei Y, Takahama Y. XCL1 and XCR1 in the immune system. Microbes Infect. 2012;14(3):262–7. Available from:
  15. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, Janani M, Sepandi M. Case fatality rate of COVID-19: A systematic review and meta-analysis. Vol. 62, Journal of Preventive Medicine and Hygiene. Pacini Editore S.p.A./AU-CNS; 2021. p. E311–20.
  16. Valero-Bover D, Monterde D, Carot-Sans G, Cainzos-Achirica M, Comin-Colet J, Vela E, et al. Is Age the Most Important Risk Factor in COVID-19 Patients? The Relevance of Comorbidity Burden: A Retrospective Analysis of 10,551 Hospitalizations. Clin Epidemiol. 2023;15:811–25.
  17. Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-Díaz ZM, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(8):763–73.
  18. Jha M, Tak M, Gupta R, Sharma P, Rajpurohit V, Mathur P, et al. Relationship of anemia with COVID-19 deaths: A retrospective cross-sectional study. J Anaesthesiol Clin Pharmacol. 2022;38(5):115.
  19. Yang A-P, Liu J, Tao W, Li H. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504. Available from:
  20. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–99. Available from:
  21. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clinical Immunology. 2020;215:108427.
  22. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128. Available from:
  23. Querol-Ribelles JM, Tenias JM, Grau E, Querol-Borras JM, Climent JL, Gomez E, et al. Plasma d-Dimer Levels Correlate With Outcomes in Patients With Community-Acquired Pneumonia. Chest. 2004;126(4):1087–92.
  24. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020;18(4):844–7.
  25. Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. Thromb Haemost. 2020;120(05):876–8.
  26. Tang N. Response to “Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.” Journal of Thrombosis and Haemostasis. 2020;18(6):1520–1.
  27. Wakai A. Role of fibrin D-dimer testing in emergency medicine. Emergency Medicine Journal. 2003;20(4):319–25.
  28. Hayakawa M, Maekawa K, Kushimoto S, Kato H, Sasaki J, Ogura H, et al. High D-Dimer Levels Predict a Poor Outcome in Patients with Severe Trauma, Even with High Fibrinogen Levels on Arrival. Shock. 2016;45(3):308–14.
  29. Schutte T, Thijs A, Smulders YM. Never ignore extremely elevated D-dimer levels: they are specific for serious illness. Neth J Med. 2016;74(10):443–8.
  30. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
  31. Llitjos J, Leclerc M, Chochois C, Monsallier J, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. Journal of Thrombosis and Haemostasis. 2020;18(7):1743–6.
  32. Deshpande C. Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism? Ann Intern Med. 2020;173(5):394–5.
  33. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19. Journal of Thrombosis and Haemostasis. 2020;18(6):1324–9.
  34. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.
  35. Yufei Y, Mingli L, Xuejiao L, Xuemei D, Yiming J, Qin Q, et al. Utility of the neutrophil-to-lymphocyte ratio and C-reactive protein level for coronavirus disease 2019 (COVID-19). Scand J Clin Lab Invest. 2020;80(7):536–40.
  36. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–4.
  37. Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. 2020;17(9):1281–92.
  38. Zhang J, Cao Y, Tan G, Dong X, Wang B, Lin J, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID‐19 patients. Allergy. 2021;76(2):533–50.
  39. Montesarchio V, Parella R, Iommelli C, Bianco A, Manzillo E, Fraganza F, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8(2).
  40. Zaid Y, Doré É, Dubuc I, Archambault A-S, Flamand O, Laviolette M, et al. Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. Journal of Allergy and Clinical Immunology. 2021;148(2):368-380.e3. Available from:
  41. Schoenberger S. BLT for speed. Nat Immunol. 2003;4(10):937–9.

How to Cite

Susilo, A., Pohan, H. T., Rumende, C. M., Rengganis, I., Harahap, A., Kekalih, A., Wulandari, D., Sahbandar, I. N., & Suwarto, S. (2024). Admission C-reactive protein, D-dimer, IL-6 and XCL1/lymphotactin levels as predictors of 28-day mortality in COVID-19 patients: a prospective cohort study. Bali Medical Journal, 13(1), 513–518.




Search Panel